Tyrosine kinase inhibitorFDA-approvedSecond-line
Regorafenib
How it works
Blocks multiple tyrosine kinases involved in tumor growth and angiogenesis.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Regorafenib improved median overall survival by approximately 1.4 months compared to placebo in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Higher Doses of Regorafenib Linked to Improved Survival in Colorectal Cancer | Colorectal Cancer | observational | The median overall survival was 4.6 months for patients who received a cumulative dose of ≤4200 mg and 9.8 months for those who received >4200 mg. | Source → |
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
| Combining cancer drugs shows moderate benefits for colorectal cancer patients | Colorectal Cancer | meta-analysis | The overall response rate was 6% and the median overall survival was 13.08 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.